New Drug – Striverdi Respimat – is now available as treatment for COPD.
On July 31, 2014, the United States Food and Drug Administration approved olodaterol (brand name: Striverdi Respimat) for the once daily treatment of COPD. Olodaterol is a long-acting beta-agonist (appreviated: LABA) bronchodilator that relaxes the muscle that wraps around breathing tubes (airways) to make it easier to breathe.
In October 2014, Striverdi Respimat became available for use in the United State as a prescription medication.
With the Respimat device, a slow and steady inhalation is recommended in order to inhale the fine mist deep into the lower parts of your lungs. You should then hold your breath as long as possible
Striverdi Respimat is the similar to another once daily LABA bronchodilator called indacaterol (brand name: Arcapta Neohaler).
Striverdi Respimat releases a fine mist when inhaled.
With the Neohaler device, a hard and fast inhalation is recommended in order to inhale the dry powder medication deep into the lower parts of your lungs. You should then hold your breath as long as possible.
Because Striverdi Respimat and Arcapta Neohaler are the same class of bronchodilator (called LABA), you should only use one of these medications each day. Both Striverdi Respirmat and Arcapta Neohaler can be used with the other class of bronchodilator called a long-acting muscarinic antagonist (abbreviated: LAMA). LAMA medications include
ipratropium (Atrovent), aclidinium (Tudorza), tiotropium (Spriva), and umeclidinium (Incruse). Studies show that use of both LABA and LAMA bronchodilators together are more effective than use of one of these medications alone.
Neither Striverdi Respimat nor Arcapta Neohaler is approved for use in those with asthma. Also, these medications are not to be used if you experienced sudden breathing difficulty. If that occurs, you should use your albuterol either in an inhaler or with a nebulizer.
Arcapta Neohaler is a once daily dry powder bronchodilator